Companies › REGENXBIO
2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 3; Neurology, Metabolic and endocrine; next expected readout Apr 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| RGX-121-3102 Recombinant adeno-associated virus serotype 9 (AAV9) delivering human iduronate-2-sulfatas | IDS | Phase 3 | MPS II; Mucopolysaccharidosis Type II (MPS II) | Apr 2028 |
| RGX-202 Recombinant AAV8 gene therapy delivering novel microdystrophin transgene with C-terminal d | DMD | Phase 2 | Duchenne Muscular Dystrophy | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03566043 | RGX-121-3102 | Phase 2 | Mucopolysaccharidosis Type II (MPS II) | Metabolic and endocrine | Nov 2023 |
| NCT07236606 | RGX-121-3102 | Phase 3 | MPS II | Metabolic and endocrine | Apr 2028 |
| NCT05693142 | RGX-202 | Phase 2 | Duchenne Muscular Dystrophy | Neurology | Jun 2028 |
Cash and short-term investments of $251m on 2026-09-30; operating cash outflow about $134m a year; runway about 22 months at that burn, to Aug 2028; 2 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Dyne Therapeutics Neurogene Nippon Shinyaku Stoke Therapeutics Grace Science
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.